|

EV Clinical Trials

2 actively recruiting trials across 2 locations

Also known as: AGS 22M6E, AGS-22CE

Pipeline

Phase 3: 1Phase 1/2: 1

Top Sponsors

  • Merck Sharp & Dohme LLC1
  • Eli Lilly and Company1

Indications

  • Cancer2
  • Carcinoma, Transitional Cell1
  • Urinary Bladder Neoplasms1
  • Neoplasm Metastasis1
  • Bladder Cancer1

Huntsville, Alabama1 trial

A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract

Clearview Cancer Institute

Phase 3

San Francisco, California1 trial

KEYMAKER-U04 Substudy 04D: A Clinical Study of New Treatments Given With Enfortumab Vedotin and Pembrolizumab in People With Urothelial Cancer (MK-3475-04D/KEYMAKER-U04)

UCSF Medical Center at Mission Bay ( Site 5044)

Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.